



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/00</b>		A2	(11) International Publication Number: <b>WO 99/45908</b>																
			(43) International Publication Date: 16 September 1999 (16.09.99)																
(21) International Application Number: PCT/US99/05326 (22) International Filing Date: 11 March 1999 (11.03.99) (30) Priority Data: 60/077,552 11 March 1998 (11.03.98) US (71) Applicant (for all designated States except US): OHIO STATE UNIVERSITY RESEARCH FOUNDATION [US/US]; 1960 Kenny Road, Columbus, OH 43210-1063 (US). (71)(72) Applicant and Inventor: WILLIAMS, James, W. [US/US]; 655 Superior, Oak Park, IL 60302 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): CHONG, Anita [MY/US]; 1342 W. Hood Avenue, Chicago, IL 60660 (US). WALDMAN, W., James [US/US]; 3160 Delburn Avenue, Dublin, OH 43017 (US). (74) Agent: RIN-LAURES, Li-Hsien; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606-6402 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published Without international search report and to be republished upon receipt of that report.																	
(54) Title: ANTI-VIRAL USES OF LEFLUNOMIDE PRODUCTS																			
(57) Abstract																			
The present invention relates to anti-viral uses of leflunomide product, alone or in combination with other anti-viral agents, or in combination with a pyrimidine such as uridine.																			
<table border="1"> <caption>Plaque assay results (% of untreated control)</caption> <thead> <tr> <th>Organ</th> <th>CMV</th> <th>CMV+ LEF</th> <th>CMV+ GCV</th> </tr> </thead> <tbody> <tr> <td>Salivary gland</td> <td>100</td> <td>~28</td> <td>~18</td> </tr> <tr> <td>Spleen</td> <td>100</td> <td>~28</td> <td>~10</td> </tr> <tr> <td>Lung</td> <td>100</td> <td>~2</td> <td>~2</td> </tr> </tbody> </table>				Organ	CMV	CMV+ LEF	CMV+ GCV	Salivary gland	100	~28	~18	Spleen	100	~28	~10	Lung	100	~2	~2
Organ	CMV	CMV+ LEF	CMV+ GCV																
Salivary gland	100	~28	~18																
Spleen	100	~28	~10																
Lung	100	~2	~2																